ARTICLE SUMMARY:
Thrive Earlier Detection’s eye-catching debut underscores the tantalizing reality that one of liquid biopsy’s most ambitious projects, a multi-cancer blood screening test, might be achievable, but even with the involvement of veteran scientists and executives, the start-up has a lot to prove.
The debut of Thrive Earlier Detection Corp. last spring was hard to miss: a molecular diagnostics company with a stated goal of curing cancer by diagnosing it at the earliest stages, starting life with a team of world-renowned scientific founders and a $110 million Series A.
